Gö6976 #12060

Gö6976 is supplied as a lyophilized powder. For a 1 mM stock, reconstitute the 500 µg in 1.32 ml DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used as a pretreatment at 0.1-10 µM for 0.5-1 hr prior to treating with a stimulator or is used alone with varying treatment times lasting up to 24 hr. Soluble in DMSO at 25 mg/ml; very poorly soluble in ethanol and water with maximum solubility in water at ~1-5 µM.

Storage: Store lyophilized or in solution at -20ºC, desiccated. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Molecular Weight:

378.43 g/mol

Purity:

>99%

Molecular Formula:

C₂₄H₁₈N₄O

Gö6976 is an ATP-competitive PKC inhibitor specific for Ca²⁺-dependent PKCα (IC₅₀ = 2.3 nM) and PKCβ1 (IC₅₀ = 6.2 nM) isozymes (1). It is also a potent inhibitor of PKD (IC₅₀ = 20 nM) (2). Researchers have demonstrated that Gö6976 blocks JNK activation (3-5) and inhibits PKCα-mediated, TPA-stimulated phosphorylation of CREB at Ser133 (6,7). Gö6976 is also an effective inhibitor of the tyrosine kinases Jak2 and FLT3 (8), as well as TrkA and TrkB (9).

1.  Martiny-Baron, G. et al. (1993) J. Biol. Chem. 268, 9194-9197.

2.  Gschwendt, M. et al. (1996) FEBS Lett 392, 77-80.

3.  López-Bergami, P. et al. (2005) Mol Cell 19, 309-20.

4.  Wen, J. et al. (2011) J Neuroinflammation 8, 38.

5.  Lemonnier, J. et al. (2004) J Biol Chem 279, 259-64.

6.  Chung, Y.W. et al. (2011) J Biol Chem 286, 29681-90.

7.  Paruchuri, S. and Sjölander, A. (2003) J Biol Chem 278, 45577-85.

8.  Grandage, V.L. et al. (2006) Br J Haematol 135, 303-16.

9.  Behrens, M.M. et al. (1999) J Neurochem 72, 919-24.

• Data sheet (70KB)
• MSDS PDF